1. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA 1988; 85: 3044-3048.
2. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91(11): 943–949.
3. Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000; 88(6): 1393–1402.
4. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77(11): 2318–2324.
5. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010; 28: 2114–2122.
6. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143–2153.
7. Schwartz GF, Hughes KS, Lynch HT, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, and risk management, April 2007. Breast J 2009; 15: 4–16.
8. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations ina population-based series of breast cancer cases. Br J Cancer 2000; 83: 1301–1308.
9. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9: 221-236.
10. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005; 23: 1656-1663.
11. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336(20): 1401-1408.
12. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25(11): 1329-1333.
13. Ford D, Easton DF, Stratton M, et al. Genetic heterogenity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3): 676– 689.
14. Thompson D, Easton DF. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Nat Cancer Inst 2002; 94(18): 1358–1365.
15. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18): 1365–1372.
16. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. J Hum Genet 2003; 72(5): 1117–1130.
17. Foretová L, Macháčková E, Navratilová M, Pavlů H, Hrubá M, Lukešová M, Valík D. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat 2004; 23(4): 397-398.
18. Foretová L, Macháčková E, Palácová M, Navrátilová M, Svoboda M, Petráková K. Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome. Klin Onkol 2016; 29(Suppl 1): S9-13.
19. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH,van de Vijver MJ, eds. WHO Classification of Tumours of the Breast.(4th ed). Lyon IARC; 2012.
20. Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58(8): 1588-1592.
21. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21(1): 134-147.
22. Longacre TA, Ennis M, Quenneville LA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 2006; 19(2): 195-207.
23. Gaffey MJ, Mills SE, Frierson HF Jr, Zarbo RJ, Boyd JC, Simpson JF, Weiss LM. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod Pathol 1995; 8(1): 31-38.
24. van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol 2011; 34(2): 71-88.
25. Waddell N, Arnold J, Cocciardi S, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2010; 123(3): 661-677.
26. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009; 11(4): R47.
27. Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 2008; 14(7): 1976-1983.
28. Colombo M, Giarola M, Mariani L, et al. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Mod Pathol 2008; 21(10): 1262-1270.
29. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26(26): 4282-4288.
30. Tung N, Miron A, Schnitt SJ, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010; 12: R95.
31. Yu JH, Lee JW, Son BH, et al. Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry. J Breast Cancer 2014; 17(2): 129-135.
32. Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 2009; 3: 63-76.
33. Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients. BMC Res Notes 2016; 9(1): 248.
34. Brekelmans CT, Seynaeve C, Menke-Pluymers M al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006; 17(3): 391-400.
35. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007; 43(2): 238-257.
36. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357(2): 115-123.
37. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-321.
38. Templeton AJ, Gonzalez LD, Vera-Badillo FE, et al. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PLoS One 2016; 11(5): e0154789.
39. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61(10): 4092-4097.
40. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90(15): 1138–1145.
41. Isern AE, Loman N, Malina J, Olsson H, Ringberg A. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol 2008; 34(10): 1148-1154.
42. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003; 21(1): 41-45.
43. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003; 97(7): 1601-1608.
44. Hermsen BB, van Diest PJ, Berkhof J, et al. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006; 119(6): 1412-1418.
45. Arun B, Vogel KJ, Lopez A, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2009; 2(2): 122-127.
46. van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol 2009; 62(10): 926-930.
47. Yang RL, Mick R, Lee K, et al. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. J Transl Med 2015; 13: 335.
48. Gulbahce HE, Vanderwerf S, Blair C, Sweeney C. Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer. Hum Pathol 2014; 45(1): 78-84.
49. Hermsen BB, von Mensdorff-Pouilly S, Fabry HF, Winters HA, Kenemans P, Verheijen RH, van Diest PJ. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J Pathol 2005; 206(2): 220-223.
50. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological features of non-neoplastic breast parenchyma do not predict BRCA mutation status of patients with invasive breast cancer. Biomark Cancer 2015; 7: 39-49.
51. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31(3): 860–867.
52. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. Ann Oncol 2014; 25: 1544–1450.
53. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocites in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959–2967.
54. Denkert C, Minckwitz G, Brasen JA, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple negative primary breast cancers. J Clin Oncol 2015; 33: 983–991.
55. Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer. Ann Oncol 2016; 27(2): 249-56.
56. Hornychová H, Melichar B, Tomšová M, Mergancová J, Urminská H, Ryška A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008; 26(10): 1024-1031.
57. Yu X, Zhang Z, Wang Z, Wu P, Qiu F, Huang J. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol 2016; 18(5) :497-506.
58. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol 2016 Jun 23. doi: 10.1001/jamaoncol.2016.1061.
59. Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. 2016; 11(4): e0152500. doi: 10.1371/journal.pone.0152500.
60. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008; 45: 425-431.
61. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11(14): 5175-5180.
62. Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009; 33(7): 1093-1097.
63. Chang J, Hilsenbeck SG, Sng JH, et al. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 2001; 7: 1739-1742.
64. Hassanein M, Huiart L, Bourdon Vet al. Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. Pathobiology 2013; 80(5): 219-227.
65. Burgess M, Puhalla S. BRCA 1/2 mutation related and sporadic breast and ovarian cancers: more alike than different. Front Oncol 2014; 4(19): 1-15.